Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anixa Biosciences IncITUS · Entity 6698 | Director | September 22, 2017 | September 26, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anixa Biosciences Inc
Report date September 22, 2017 · Filed September 26, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 604,817 |
Reported balance
After 2017-09-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-09-22 · Grant · Acquired 50,000 · Balance 604,817 F1: Stock Award granted under the ITUS Corporation 2010 Share Incentive Plan (the "Plan"). |
| Employee Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.27 · Expires 2027-09-22 | Direct | 50,000 |
Reported balance
After 2017-09-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-09-22 · Grant · Acquired 50,000 · Balance 50,000 F2: Right-To-Buy, pursuant to the Plan. F3: The options vest and become exercisable in four (4) equal installments on each of December 31, 2017, March 31, 2018, June 30, 2018 and September 30, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock Award granted under the ITUS Corporation 2010 Share Incentive Plan (the "Plan").
F2: Right-To-Buy, pursuant to the Plan.
F3: The options vest and become exercisable in four (4) equal installments on each of December 31, 2017, March 31, 2018, June 30, 2018 and September 30, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 22, 2017 Filed Sep 26, 2017 19:49 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | GrantEmployee Stock Options (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001513162-17-000264 · primary_doc.xml · derivative · entry 2 JOHNSON BRUCE F · CIK 0001212827 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-09-22 F2 · security: Right-To-Buy, pursuant to the Plan. F3 · derivative.exercise_date: The options vest and become exercisable in four (4) equal installments on each of December 31, 2017, March 31, 2018, June 30, 2018 and September 30, 2018. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 19:49 UTC | Anixa Biosciences Inc ITUS · Entity 6698 | GrantCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001513162-17-000264 · primary_doc.xml · nonDerivative · entry 1 JOHNSON BRUCE F · CIK 0001212827 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 604,817 F1 · security: Stock Award granted under the ITUS Corporation 2010 Share Incentive Plan (the "Plan"). F1 · price: Stock Award granted under the ITUS Corporation 2010 Share Incentive Plan (the "Plan"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.